Oculis Advances Privosegtor into PIONEER Registrational Trials for Optic Neuritis
Event summary
- Oculis to present Privosegtor data at Clinical Trials at the Summit 2026 on June 13, 2026.
- Privosegtor received Breakthrough Therapy designation from FDA and PRIME designation from EMA for optic neuritis.
- PIONEER registrational program includes trials for optic neuritis and non-arteritic anterior ischemic optic neuropathy (NAION).
- Phase 2 ACUITY trial showed improvements in visual function and anatomical preservation of the retina.
The big picture
Oculis' advancement of Privosegtor into late-stage clinical trials marks a significant step in addressing the unmet medical needs in neuro-ophthalmology. The regulatory designations and positive Phase 2 data position Privosegtor as a potential first-in-class neuroprotective therapy, which could reshape the treatment landscape for optic neuritis and related conditions. The broader applicability of Privosegtor in other neurological diseases adds strategic depth to Oculis' pipeline.
What we're watching
- Regulatory Momentum
- Whether the Breakthrough Therapy and PRIME designations will accelerate Privosegtor's path to market.
- Clinical Trial Success
- The pace at which the PIONEER registrational trials will yield positive results for optic neuritis and NAION.
- Market Expansion
- How Privosegtor's potential applicability in other neuro-ophthalmic and neurological diseases will impact Oculis' strategic direction.